Bisphosphonates and osteonecrosis of the mandible/maxilla in osteoporosis: no reason to panic.
Identifieur interne : 000394 ( Main/Exploration ); précédent : 000393; suivant : 000395Bisphosphonates and osteonecrosis of the mandible/maxilla in osteoporosis: no reason to panic.
Auteurs : Francesco Bertoldo [Italie]Source :
- Aging clinical and experimental research [ 1594-0667 ] ; 2008.
Descripteurs français
- KwdFr :
- Diphosphates (effets indésirables), Diphosphates (usage thérapeutique), Facteurs de risque (MeSH), Femelle (MeSH), Humains (MeSH), Maladies de la mâchoire (induit chimiquement), Maladies de la mâchoire (prévention et contrôle), Mâle (MeSH), Os et tissu osseux (métabolisme), Ostéonécrose (induit chimiquement), Ostéonécrose (prévention et contrôle), Ostéoporose (traitement médicamenteux), Relation dose-effet des médicaments (MeSH), Tumeurs osseuses (traitement médicamenteux).
- MESH :
- effets indésirables : Diphosphates.
- induit chimiquement : Maladies de la mâchoire, Ostéonécrose.
- métabolisme : Os et tissu osseux.
- prévention et contrôle : Maladies de la mâchoire, Ostéonécrose.
- traitement médicamenteux : Ostéoporose, Tumeurs osseuses.
- usage thérapeutique : Diphosphates.
- Facteurs de risque, Femelle, Humains, Mâle, Relation dose-effet des médicaments.
English descriptors
- KwdEn :
- Bone Neoplasms (drug therapy), Bone and Bones (metabolism), Diphosphates (adverse effects), Diphosphates (therapeutic use), Dose-Response Relationship, Drug (MeSH), Female (MeSH), Humans (MeSH), Jaw Diseases (chemically induced), Jaw Diseases (prevention & control), Male (MeSH), Osteonecrosis (chemically induced), Osteonecrosis (prevention & control), Osteoporosis (drug therapy), Risk Factors (MeSH).
- MESH :
- chemical , adverse effects : Diphosphates.
- chemically induced : Jaw Diseases, Osteonecrosis.
- drug therapy : Bone Neoplasms, Osteoporosis.
- metabolism : Bone and Bones.
- prevention & control : Jaw Diseases, Osteonecrosis.
- chemical , therapeutic use : Diphosphates.
- Dose-Response Relationship, Drug, Female, Humans, Male, Risk Factors.
Abstract
Bisphosphonate (BP) therapy has modified the natural history of many bone metabolic diseases. Amino-bisphosphonates nowadays represent the primary therapeutic choice for the treatment of osteoporosis and for prevention of fractures. Osteonecrosis of the mandible and maxilla (ONJ) is a rare disease usually occurring in cancer patients with bone metastases treated with high doses of intravenous BPs. Some cases have been described in patients taking amino-BPs for osteoporosis, but the specific drug utilized, its dosage and use of the oral route have reduced that risk considerably (estimated at 1/100,000 subjects a year). Prevention of ONJ include good oral hygiene habits in all patients and, in a subject who has been treated for more than three years, conservative dental procedures when possible, an appropriate antibiotic therapy and a careful follow-up when invasive oral interventions are necessary, are recommended by dentists and bone metabolism experts alike.
DOI: 10.1007/BF03324753
PubMed: 18283234
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Bisphosphonates and osteonecrosis of the mandible/maxilla in osteoporosis: no reason to panic.</title><author><name sortKey="Bertoldo, Francesco" sort="Bertoldo, Francesco" uniqKey="Bertoldo F" first="Francesco" last="Bertoldo">Francesco Bertoldo</name><affiliation wicri:level="1"><nlm:affiliation>Unit of Diseases of Mineral Metabolism and of the Bone, Department of Biomedical and Surgical Sciences, University of Verona, 37124 Verona, Italy. francesco.bertoldo@univr.it</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Unit of Diseases of Mineral Metabolism and of the Bone, Department of Biomedical and Surgical Sciences, University of Verona, 37124 Verona</wicri:regionArea><wicri:noRegion>37124 Verona</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2008">2008</date><idno type="RBID">pubmed:18283234</idno><idno type="pmid">18283234</idno><idno type="doi">10.1007/BF03324753</idno><idno type="wicri:Area/Main/Corpus">000390</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000390</idno><idno type="wicri:Area/Main/Curation">000390</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000390</idno><idno type="wicri:Area/Main/Exploration">000390</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Bisphosphonates and osteonecrosis of the mandible/maxilla in osteoporosis: no reason to panic.</title><author><name sortKey="Bertoldo, Francesco" sort="Bertoldo, Francesco" uniqKey="Bertoldo F" first="Francesco" last="Bertoldo">Francesco Bertoldo</name><affiliation wicri:level="1"><nlm:affiliation>Unit of Diseases of Mineral Metabolism and of the Bone, Department of Biomedical and Surgical Sciences, University of Verona, 37124 Verona, Italy. francesco.bertoldo@univr.it</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Unit of Diseases of Mineral Metabolism and of the Bone, Department of Biomedical and Surgical Sciences, University of Verona, 37124 Verona</wicri:regionArea><wicri:noRegion>37124 Verona</wicri:noRegion></affiliation></author></analytic><series><title level="j">Aging clinical and experimental research</title><idno type="ISSN">1594-0667</idno><imprint><date when="2008" type="published">2008</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Bone Neoplasms (drug therapy)</term><term>Bone and Bones (metabolism)</term><term>Diphosphates (adverse effects)</term><term>Diphosphates (therapeutic use)</term><term>Dose-Response Relationship, Drug (MeSH)</term><term>Female (MeSH)</term><term>Humans (MeSH)</term><term>Jaw Diseases (chemically induced)</term><term>Jaw Diseases (prevention & control)</term><term>Male (MeSH)</term><term>Osteonecrosis (chemically induced)</term><term>Osteonecrosis (prevention & control)</term><term>Osteoporosis (drug therapy)</term><term>Risk Factors (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Diphosphates (effets indésirables)</term><term>Diphosphates (usage thérapeutique)</term><term>Facteurs de risque (MeSH)</term><term>Femelle (MeSH)</term><term>Humains (MeSH)</term><term>Maladies de la mâchoire (induit chimiquement)</term><term>Maladies de la mâchoire (prévention et contrôle)</term><term>Mâle (MeSH)</term><term>Os et tissu osseux (métabolisme)</term><term>Ostéonécrose (induit chimiquement)</term><term>Ostéonécrose (prévention et contrôle)</term><term>Ostéoporose (traitement médicamenteux)</term><term>Relation dose-effet des médicaments (MeSH)</term><term>Tumeurs osseuses (traitement médicamenteux)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Diphosphates</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Jaw Diseases</term><term>Osteonecrosis</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Bone Neoplasms</term><term>Osteoporosis</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Diphosphates</term></keywords><keywords scheme="MESH" qualifier="induit chimiquement" xml:lang="fr"><term>Maladies de la mâchoire</term><term>Ostéonécrose</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Bone and Bones</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Os et tissu osseux</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Jaw Diseases</term><term>Osteonecrosis</term></keywords><keywords scheme="MESH" qualifier="prévention et contrôle" xml:lang="fr"><term>Maladies de la mâchoire</term><term>Ostéonécrose</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Diphosphates</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Ostéoporose</term><term>Tumeurs osseuses</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Diphosphates</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Dose-Response Relationship, Drug</term><term>Female</term><term>Humans</term><term>Male</term><term>Risk Factors</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Facteurs de risque</term><term>Femelle</term><term>Humains</term><term>Mâle</term><term>Relation dose-effet des médicaments</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Bisphosphonate (BP) therapy has modified the natural history of many bone metabolic diseases. Amino-bisphosphonates nowadays represent the primary therapeutic choice for the treatment of osteoporosis and for prevention of fractures. Osteonecrosis of the mandible and maxilla (ONJ) is a rare disease usually occurring in cancer patients with bone metastases treated with high doses of intravenous BPs. Some cases have been described in patients taking amino-BPs for osteoporosis, but the specific drug utilized, its dosage and use of the oral route have reduced that risk considerably (estimated at 1/100,000 subjects a year). Prevention of ONJ include good oral hygiene habits in all patients and, in a subject who has been treated for more than three years, conservative dental procedures when possible, an appropriate antibiotic therapy and a careful follow-up when invasive oral interventions are necessary, are recommended by dentists and bone metabolism experts alike.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18283234</PMID><DateCompleted><Year>2008</Year><Month>06</Month><Day>12</Day></DateCompleted><DateRevised><Year>2019</Year><Month>11</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1594-0667</ISSN><JournalIssue CitedMedium="Print"><Volume>20</Volume><Issue>1</Issue><PubDate><Year>2008</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Aging clinical and experimental research</Title><ISOAbbreviation>Aging Clin Exp Res</ISOAbbreviation></Journal><ArticleTitle>Bisphosphonates and osteonecrosis of the mandible/maxilla in osteoporosis: no reason to panic.</ArticleTitle><Pagination><MedlinePgn>87-90</MedlinePgn></Pagination><Abstract><AbstractText>Bisphosphonate (BP) therapy has modified the natural history of many bone metabolic diseases. Amino-bisphosphonates nowadays represent the primary therapeutic choice for the treatment of osteoporosis and for prevention of fractures. Osteonecrosis of the mandible and maxilla (ONJ) is a rare disease usually occurring in cancer patients with bone metastases treated with high doses of intravenous BPs. Some cases have been described in patients taking amino-BPs for osteoporosis, but the specific drug utilized, its dosage and use of the oral route have reduced that risk considerably (estimated at 1/100,000 subjects a year). Prevention of ONJ include good oral hygiene habits in all patients and, in a subject who has been treated for more than three years, conservative dental procedures when possible, an appropriate antibiotic therapy and a careful follow-up when invasive oral interventions are necessary, are recommended by dentists and bone metabolism experts alike.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bertoldo</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Unit of Diseases of Mineral Metabolism and of the Bone, Department of Biomedical and Surgical Sciences, University of Verona, 37124 Verona, Italy. francesco.bertoldo@univr.it</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Aging Clin Exp Res</MedlineTA><NlmUniqueID>101132995</NlmUniqueID><ISSNLinking>1594-0667</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011756">Diphosphates</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001859" MajorTopicYN="N">Bone Neoplasms</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001842" MajorTopicYN="N">Bone and Bones</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011756" MajorTopicYN="N">Diphosphates</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007571" MajorTopicYN="N">Jaw Diseases</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010020" MajorTopicYN="N">Osteonecrosis</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010024" MajorTopicYN="N">Osteoporosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>2</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>6</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>2</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18283234</ArticleId><ArticleId IdType="pii">4388</ArticleId><ArticleId IdType="doi">10.1007/BF03324753</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Italie</li></country></list><tree><country name="Italie"><noRegion><name sortKey="Bertoldo, Francesco" sort="Bertoldo, Francesco" uniqKey="Bertoldo F" first="Francesco" last="Bertoldo">Francesco Bertoldo</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SuicidDentistV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000394 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000394 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SuicidDentistV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:18283234
|texte= Bisphosphonates and osteonecrosis of the mandible/maxilla in osteoporosis: no reason to panic.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:18283234" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a SuicidDentistV1
| This area was generated with Dilib version V0.6.39. |  |